Gastroesophageal reflux disease (GERD) is a very common disorder, mainly occurring in Western countries. The nonerosive form of GERD, which occurs in more than half of the patients affected, deserves particular attention. Administering symptomatic therapy without a prior endoscopic examination has become an attractive option, since it also provides diagnostic information. Proton-pump inhibitors (PPIs) have become established as the standard therapy, but new insights into the pathophysiology of the condition may lead to new treatment options using γ-aminobutyric acid (GABA) agonists. Endoscopic therapy is still at the experimental stage and has yet to prove its value as an alternative to PPI and surgery. However, it is questionable whether antireflux surgery is more cost-effective in the longer term. Gastroenterologists are now much more aware of Barrett’s esophagus than was the case a few years ago. Barrett’s esophagus is a frequent finding in patients with reflux symptoms, but is a rare cause of death in affected patients. For several reasons, there is a large gap between recommendations regarding surveillance, on the one hand, and everyday practice on the other. New diagnostic procedures such as chromoendoscopy may allow better detection of premalignant and malignant alterations in metaplastic mucosa, but the safety of such techniques has been questioned. Prophylactic ablation is a debatable approach, whereas endoscopic interventions in patients with high-grade dysplasia and early adenocarcinoma are continuing to develop as attractive alternatives to esophagectomy in selected patients. It remains to be seen whether chemoprevention using cyclooxygenase-2 (COX-2) inhibitors should be carried out in high-risk patients with Barrett’s esophagus, in order to prevent malignant transformation to esophageal cancer.
References
1
Spechler S J, Jain S K, Tendler D A, Parker R A.
Racial differences in the frequency of symptoms and complications of gastro-oesophageal reflux disease.
Aliment Pharmacol Ther.
2002;
16
1795-1800
2
Shaker R, Castell D O, Senfeld P S, Spechler S J.
Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association.
Am J Gastroenterol.
2003;
98
1487-1493
3
Mathus-Vieen E MH, Tytgat G NJ.
Gastro-oesophageal reflux in obese subjects: influence of overweight, weight loss and chronic gastric balloon distension.
Scand J Gastroenterol.
2002;
37
1246-1252
4
Collings K L, Pierce Pratt F, Rodriguez-Stanley S. et al .
Esophageal reflux in conditioned runners, cyclists, and weightlifters.
Med Sci Sports Exerc.
2003;
35
730-735
5
Cremonini F, di Caro S, Delgado-Aros S. et al .
Meta-analysis: the relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease.
Aliment Pharmacol Ther.
2003;
18
279-289
6
Martinez S D, Malagon I B, Garewal H S. et al .
Non-erosive reflux disease (NERD): acid reflux and symptom patterns.
Aliment Pharmacol Ther.
2003;
17
537-545
7
Mäntynen T, Färkkilä M, Kunnamo I. et al .
The impact of upper GI endoscopy referral volume on the diagnosis of gastroesophageal reflux disease and its complications: 1-year cross sectional study in a referral area with 260,000 inhabitants.
Am J Gastroenterol.
2002;
97
2524-2529
9
Bowrey D J, Williams G T, Clark G W.
Histological changes in the oesophageal squamous mucosa: correlation with ambulatory 24 hour pH monitoring.
Clin Pathol.
2003;
56
205-208
10
Kawamura M, Ohara S, Koike T. et al .
The effects of lansoprazole on erosive oesophagitis are influenced by CYP 2C19 polymorphism.
Aliment Pharmacol Ther.
2003;
17
965-973
11
Dalby-Payne J R, Morris A M, Craig J C.
Meta-analysis of randomized controlled trials on the benefit and risks of using cisapride for the treatment if gastroesophageal reflux in children.
Gastroenterol Hepatol.
2003;
18
196-202
12
Ciccaglione A F, Marzio L.
Effect of acute and chronic administration of the GABAB agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease.
Gut.
2003;
52
464-470
13
Vela M F, Tutuian R, Katz P O, Castell D O.
Baclofen decreases acid and non-acid post-prandial gastroesophageal reflux measured by combined multichannel intraluminal impedance and pH.
Aliment Pharmacol Ther.
2003;
17
243-251
14
Cantu P, Carmagnola S, Savojardo D. et al .
Effect of non-selective gamma-aminobutyric acid receptor stimulation on motor function of the lower oesophageal sphincter and gastro-oesophageal reflux in healthy human subjects.
Aliment Pharmacol Ther.
2003;
18
699-704
15
Koeck G H, Sifrim D, Lerut T. et al .
Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors.
Gut.
2003;
52
1397-1402
16
Triadafilopoulos G, DiBase J K, Nostrant T T. et al .
The Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the U.S. open label trial.
Gastrointest Endosc.
2002;
55
149-156
18
Corley D A, Katz P, Wo J M. et al .
Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled study.
Gastroenterology.
2003;
125
668-676
19
Tam W C, Schoeman M N, Zhang Q. et al .
Delivery of radiofrequency energy to the lower oesophageal sphincter and gastric cardia inhibits transient lower oesophageal sphincter relaxations and gastro-oesophageal reflux in patients with reflux disease.
Gut.
2003;
52
479-485
20
Mahmood Z, McMahon B P, Arfin Q. et al .
Endocinch therapy for gastro-oesophageal reflux disease: a one year prospective follow up.
Gut.
2003;
52
34-39
21
Velanovich V, Ben-Menachem T, Goel S.
Case-control comparison of endoscopic gastroplication with laparoscopic fundoplication in the management of gastroesophageal reflux disease: early symptomatic outcome.
Surg Laparosc Endoscop Percut Tech.
2002;
12
219-223
22
Johnson D A, Ganz R, Aisenberg J. et al .
Endoscopic, deep mural implantation of Enteryx for treatment of GERD: 6-month follow-up of a multicenter trial.
Am J Gastroenterol.
2003;
98
250-258
23
Cohen J A, Arain A, Harris P A. et al .
Surgical trial investigating nocturnal gastroesophageal reflux and sleep (STRINGERS).
Surg Endosc.
2003;
17
394-400
26
Hagedorn C, Jonson C, Lonroth H. et al .
Efficacy of an anterior as compared with a posterior laparoscopic partial fundoplication: results from a randomized controlled trial.
Ann Surg.
2003;
238
189-196
27
Crysos E, Tsiaoussis J, Zoras O J. et al .
Laparoscopic surgery for gastroesophageal reflux disease with impaired esophageal peristalsis: total or partial fundoplication?.
J Am Coll Surg.
2003;
197
8-15
28
Jaspersen D, Kulig M, Labenz J. et al .
Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD study.
Aliment Pharmacol Ther.
2003;
17
1515-1520
29
Poe R H, Kallay M C.
Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment.
Chest.
2003;
123
679-684
30
Green B T, Broughton W A, O’Connor J B.
Marked improvement in nocturnal gastroesophageal reflux in a large cohort of patients with obstructive sleep apnea treated with continuous positive airway pressure.
Arch Intern Med.
2003;
163
41-45
32
Taha A S, Angerson W J, Morran C G.
Reflux and Barrett’s oesophagus after gastric surgery: long-term follow-up and implications for the roles of gastric acid and bile in oesophagitis.
Aliment Pharmacol Ther.
2003;
17
547-552
33
Kaur B S, Triadafiloloulos G.
Acid- and bile-induced PGE(2) release and hyperproliferation in Barrett’s esophagus are COX-2 and PKC-epsilon dependent.
Am J Physiol.
2002;
283
G327-334
34
Haigh C R, Attwood S EA, Thompson D G. et al .
Gastrin induces proliferation in Barrett’s metaplasia through activation of the CCK2 receptor.
Gastroenterology.
2003;
124
615-625
35
Doak S H, Jenkins G JS, Parry E M. et al .
Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett’s oesophagus.
Gut.
2003;
52
623-628
36
Fitzgerald R C, Abdala S, Onwuegbusi B A. et al .
Inflammatory gradient in Barrett’s oesophagus: implications for disease complications.
Gut.
2002;
51
316-322
37
Egger K, Werner M, Meining A. et al .
Biopsy surveillance is still necessary in patients with Barrett’s oesophagus despite new imaging techniques.
Gut.
2003;
52
18-23
38
Mandal A, Playford R J, Wicks A C.
Current practice in surveillance strategy for patients with Barrett’s oesophagus in the UK.
Aliment Pharmacol Ther.
2003;
17
1319-1324
39
Inadomi J M, Sampliner R, Lagergren J. et al .
Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis.
Ann Intern Med.
2003;
138
176-186
40
Kearny D J, Crump C, Maynard C, Boyko E J.
A case-control study of endoscopy and mortality from adenocarcinoma of the esophagus or gastric cardia in persons with GERD.
Gastrointest Endosc.
2003;
57
823-829
41
Breyer H P, de Barros S GS, Maguilnik I, Edelweiss M I.
Does methylene blue detect intestinal metaplasia in Barrett’s esophagus?.
Gastrointest Endosc.
2003;
57
505-509
42
Olliver J R, Wild C P, Sahay P. et al .
Chromoendoscopy with methylene blue and associated DNS damage in Barrett’s oesophagus.
Lancet.
2003;
362
373-374
43
Basu K K, Pick B, Bale R. et al .
Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett’s oesophagus: factors determining persistence and recurrence of Barrett’s epithelium.
Gut.
2002;
51
776-780
44
Morino M, Rebechi F, Giaccone C. et al .
Endoscopic ablation of Barrett’s esophagus using argon plasma coagulation (APC) following surgical laparoscopic fundoplication.
Surg Endosc.
2003;
17
539-542
45
Gurski R R, Peters J H, Ghagen J A. et al .
Barrett’s esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features.
J Am Coll Surg.
2003;
196
706-712
47
Parilla P, Martinez de Haro L F, Ortiz A. et al .
Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett’s esophagus.
Ann Surg.
2003;
237
291-298
48
Corley D A, Kerlekowske K, Verma R, Buffler P.
Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis.
Gastroenterology.
2003;
124
47-56
50
Attwood S AE, Lewis C J, Caplan S. et al .
Argon plasma coagulation as therapy for high-grade dysplasia in Barrett’s esophagus.
Clin Gastroenterol Hepatol.
2003;
1
258-263
51
May A, Gossner L, Pech O. et al .
Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett’s oesophagus: acute phase and intermediate results of a new treatment approach.
Eur J Gastroenterol Hepatol.
2002;
14
1085-1091
52
Pacifica R J, Wang K K, Wongkeesong L M. et al .
Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett’s esophagus.
Clin Gastroenterol Hepatol.
2003;
1
252-257
